NasdaqGS - Nasdaq Real Time Price USD
Bio-Techne Corporation (TECH)
59.37 +3.11 (+5.53%)
As of 11:41:44 AM EDT. Market Open.
Trade TECH on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for TECH
- Previous Close
56.26 - Open
57.11 - Bid 55.32 x 200
- Ask 64.24 x 200
- Day's Range
56.85 - 60.25 - 52 Week Range
43.20 - 72.16 - Volume
1,239,845 - Avg. Volume
2,689,774 - Market Cap (intraday)
9.295B - Beta (5Y Monthly) 1.36
- PE Ratio (TTM)
84.81 - EPS (TTM)
0.70 - Earnings Date (est.) Aug 5, 2026
- Forward Dividend & Yield 0.32 (0.57%)
- Ex-Dividend Date May 18, 2026
- 1y Target Est
61.31
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
TECH
1.28%
S&P 500 (^GSPC)
8.31%
1-Year Return
TECH
19.46%
S&P 500 (^GSPC)
21.70%
3-Year Return
TECH
21.30%
S&P 500 (^GSPC)
70.51%
5-Year Return
TECH
44.74%
S&P 500 (^GSPC)
73.78%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
8.81B
Enterprise Value
8.89B
Trailing P/E
80.41
Forward P/E
27.62
PEG Ratio (5yr expected)
0.78
Price/Sales (ttm)
7.30
Price/Book (mrq)
4.23
Enterprise Value/Revenue
7.35
Enterprise Value/EBITDA
34.59
Financial Highlights
Profitability and Income Statement
Profit Margin
9.05%
Return on Assets (ttm)
7.45%
Return on Equity (ttm)
5.34%
Revenue (ttm)
1.21B
Net Income Avi to Common (ttm)
109.5M
Diluted EPS (ttm)
0.70
Balance Sheet and Cash Flow
Total Cash (mrq)
214.11M
Total Debt/Equity (mrq)
13.92%
Levered Free Cash Flow (ttm)
299.85M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
18.61
+8.03%
Mkt Cap 2.979B
Industry Diagnostics & Research
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreThe major indices are higher at midday on Thursday. Many trading charts so far
The major indices are higher at midday on Thursday. Many trading charts so far today look like a roller coaster as investors react to headlines. To that end, President Trump says the U.S. will continue to strike if Iran doesn't agree to an interim peace deal; inflation on the wholesale side moved higher in May; and the entire world (it seems) is awaiting the IPO of SpaceX.
Management sees stronger growth in second half
Based in Minneapolis, Bio-Techne develops and markets protein-based instruments and reagents for research and clinical use. Its customers include companies in the pharmaceutical and biotech industries, as well as academic research institutions. The company's products and solutions aid in drug discovery and provide the means for accurate clinical tests and diagnoses. Through its Protein Sciences business segment, Bio-Techne is one of the world's leading suppliers of proteins, such as cytokines and growth factors, immunoassays, antibodies, and reagents to the biotech and academic research communities. The Diagnostics and Spatial Biology segment provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays, and other bulk and custom reagents for the in-vitro diagnostic market.
RatingPrice TargetBio-Techne Earnings: Softness in Biotech Demand Continues to Weigh on Top-Line Growth
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
RatingPrice TargetBio-Techne Earnings: Softness in Biotech Demand Continues to Weigh on Top-Line Growth
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
RatingPrice Target